Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

First of its Kind IMBRUVICA® (ibrutinib) Developed for the Treatment of Chronic Graft-Versus-Host Disease (cGVHD)

The Janssen Pharmaceutical Companies of Johnson & Johnson developed IMBRUVICA® (ibrutinib) the first and only treatment for Chronic Graft-Versus-Host Disease in pediatric patients.

IMBRUVICA® is the only BTKi treatment approved by FDA applicable for individuals with one year and older with chronic graft-versus-host disease (cGVHD) regardless of one or more systemic therapy failures.

IMBRUVICA® is the new oral suspension formulation approved for this life-threatening disease for younger patient’s aging one to less than 12 who had no prior treatment options for cGVHD.

IMB­RUVICA® (ibrutinib) is a once-daily oral medication which blocks the Bruton’s tyrosine kinase (BTK) protein required for normal and abnormal B cells to multiply and spread.

IMBRUVICA® blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B cells, including specific cancer cells, to multiply and spread. With the BTK blockage, IMBRUVICA® helps abnormal B cells in moving out of their nourishing environments in the lymph nodes, bone marrow, and other organs.

Globally 250,000 patients are treated with IMBRUVICA® and it is approved in more than 100 countries. Most common symptoms of cGVHD include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damaged lungs.

U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients with chronic graft-versus-host disease (cGVHD).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024